Patents Assigned to GelTex Pharmaceutical, Inc.
-
Publication number: 20020081340Abstract: The invention relates to the unexpected discovery that bismuth-containing compounds are effective in the treatment of oral mucositis in a mammal. Thus, the invention relates, in one aspect to a method of treating oral mucositis comprising administering an effective amount of a pharmaceutically acceptable bismuth-containing compound, such as a bismuth salt or bismuth complex. In a preferred embodiment, the bismuth compound is an organic or inorganic salt such as, bismuth subsalicylate, bismuth subgallate, bismuth aluminate, bismuth citrate, bismuth subcitrate, bismuth carbonate, bismuth subcarbonate, tripotassium dicitrato bismuthate, bismuth nitrate, bismuth subnitrate, bismuth tartrate and mixtures thereof, preferably, bismuth subsalicylate and bismuth subgallate.Type: ApplicationFiled: June 8, 2001Publication date: June 27, 2002Applicant: GelTex Pharmaceuticals, Inc.Inventors: Philip J. Goddard, Jeffrey D. Klinger, Pradeep K. Dahl, W. Harry Mandeville, Richard J. Fitzpatrick, Thomas X. Neenan
-
Patent number: 6395777Abstract: A method for treating a microbial infection in a mammal, such as a human, comprising treating the mammal with a therapeutically effective amount of a polymer comprising an amino group or an ammonium group attached to the polymer backbone via an aliphatic spacer group. The polymer can be a homopolymer or a copolymer. In one embodiment, the polymer is a copolymer comprising a monomer having a pendant ammonium group and a hydrophobic monomer.Type: GrantFiled: January 28, 2000Date of Patent: May 28, 2002Assignee: GelTex Pharmaceuticals, Inc.Inventors: W. Harry Mandeville, III, Thomas X. Neenan, Stephen Randall Holmes-Farley
-
Patent number: 6365186Abstract: The invention relates to methods for treating hypercholesterolemia and atherosclerosis, and reducing serum cholesterol in a mammal. The methods of the invention comprise administering to a mammal a first amount of a bile acid sequestrant compound which is an unsubstituted polydiallylamine polymer and a second amount of a cholesterol-lowering agent. The first and second amounts together comprise a therapeutically effective amount. The invention further relates to pharmaceutical compositions useful for the treatment of hypercholesterolemia and atherosclerosis, and for reducing serum cholesterol. The pharmaceutical compositions comprise a combination of a first amount of an unsubstituted polydiallylamine polymer compound and a second amount of a cholesterol-lowering agent. The first and second amounts comprise a therapeutically effective amount. The pharmaceutical compositions of the present invention may optionally contain a pharmaceutically acceptable carrier.Type: GrantFiled: May 13, 1999Date of Patent: April 2, 2002Assignee: GelTex Pharmaceuticals, Inc.Inventors: Chad Cori Huval, Stephen Randall Holmes-Farley, John S. Petersen, Pradeep K. Dhal
-
Publication number: 20020034491Abstract: The present invention relates to the discovery that certain anionic polymers have useful antibacterial activity.Type: ApplicationFiled: May 1, 2001Publication date: March 21, 2002Applicant: GelTex Pharmaceuticals, Inc.Inventors: Richard J. Fitzpatrick, Robert H. Barker
-
Patent number: 6352692Abstract: The invention features a method for treating obesity in a patient by administering to the patient a polymer that has been substituted with one or more groups that inhibit lipases, which are enzymes responsible for the hydrolysis of fat. The invention further relates to the polymers employed in the methods described herein as well as novel intermediates and methods for preparing the polymers.Type: GrantFiled: January 6, 1999Date of Patent: March 5, 2002Assignee: GelTex Pharmaceuticals, Inc.Inventors: W. Harry Mandeville, III, Molly Kate Boie, Venkata R. Garigapati
-
Publication number: 20020015946Abstract: The present invention relates to a method of treating a viral infection in an animal, such as a human, by administering to the animal a therapeutically effective amount of a polymer comprising a plurality of pendant hydrophobic groups and a plurality of pendant acid functional groups. The acid functional groups are connected directly to the polymer backbone or via an aliphatic spacer group of 1 to about 20 atoms in length.Type: ApplicationFiled: June 11, 2001Publication date: February 7, 2002Applicant: GelTex Pharmaceuticals, Inc.Inventors: Thomas X. Neenan, W. Harry Mandeville,
-
Publication number: 20010051660Abstract: A method for reducing oxalate levels in a patient that includes administering to the patient a therapeutically effective amount of non-absorbable amine polymers such as a polymer characterized by a repeat unit having the formula: 1Type: ApplicationFiled: June 26, 2001Publication date: December 13, 2001Applicant: GelTex Pharmaceutical, Inc.Inventors: Stephen Randall Holmes-Farley, W. Harry Mandeville,
-
Publication number: 20010044519Abstract: The invention relates to a method for removing bile salts from a patient in need thereof and compositions useful in the method. The method comprises administering to the patient a therapeutically effective amount of a salt of an alkylated and crosslinked polymer. The alkylated and crosslinked polymer salt comprises the reaction product of crosslinked polymers, or salts and copolymers thereof having amine containing repeat units, with at least one aliphatic alkylating agent.Type: ApplicationFiled: March 9, 2001Publication date: November 22, 2001Applicant: GelTex Pharmaceuticals, Inc.Inventors: W. Harry Mandeville, III, Stephen Randall Holmes-Farley
-
Publication number: 20010041171Abstract: The present invention relates to a method of inhibiting a toxin in an animal, such as a human, by administering to the animal a therapeutically effective amount of a polymer having a plurality of pendant acid functional groups which are directly attached to the polymer backbone or attached to the polymer backbone by a spacer group. The spacer group can have a length in the range from 0 to about 20 atoms. The toxin is, typically, an exotoxin secreted by a pathogenic microorganism, such as a bacterium.Type: ApplicationFiled: June 11, 2001Publication date: November 15, 2001Applicant: GelTex Pharmaceuticals, Inc.Inventors: Caroline Isabelle Bacon Kurtz, Richard Fitzpatrick
-
Patent number: 6299868Abstract: The present invention relates to a method for treating obesity, a method for reducing the absorption of dietary fat, and a method for treating hypertriglyceridemia in a patient and to particular polymers for use in the methods or in a manufacture of a medicament. The methods comprise the step of orally administering to a mammal, such as a human, a therapeutically effective amount of one or more fat-binding polymers. The administration of the fat-binding polymer of the invention facilitates the removal of fat from the body prior to digestion, with minimal side effects and low toxicity. In a preferred embodiment, the one or more fat-binding polymers are administered in combination with one or more lipase inhibitors, for example, lipstatin and tetrahydrolipstatin.Type: GrantFiled: July 14, 1999Date of Patent: October 9, 2001Assignee: GelTex Pharmaceuticals, Inc.Inventors: Thomas Jozefiak, Stephen Randall Holmes-Farley, W. Harry Mandeville, III, Chad Cori Huval, Venkata R. Garigapati, Keith K. Shackett, Danny Concagh
-
Patent number: 6294163Abstract: The present invention relates to a method for sequestering bile acids in a patient and to particular polymers for use in the method. The method comprises administering a therapeutically effective amount of a guanidinium moiety-containing polymer composition to a mammal, such as a human, whereby bile acids are sequestered. The polymers of the invention comprise guanidinium moieties and optionally, additional substituents such as a hydrophobic group, a quaternary ammonium-containing group or a combination thereof.Type: GrantFiled: October 2, 1998Date of Patent: September 25, 2001Assignee: GelTex Pharmaceuticals, Inc.Inventors: Pradeep K. Dhal, Stephen R. Holmes-Farley, John S. Petersen
-
Patent number: 6290947Abstract: A method for treating pathogenic toxins in a mammal, such as a human, comprising treating the mammal with a therapeutically effective amount of a polymer comprising a cationic group attached to the polymer backbone. The polymer can be a homopolymer or a copolymer. In one embodiment, the polymer is a copolymer comprising a monomer having a pendant ammonium group and a hydrophobic monomer.Type: GrantFiled: June 19, 2000Date of Patent: September 18, 2001Assignee: GelTex Pharmaceuticals, Inc.Inventors: Richard Fitzpatrick, Chad Cori Huval, Caroline Isabelle Bacon Kurtz, W. Harry Mandeville, III, Thomas X. Neenan
-
Patent number: 6290946Abstract: The present invention relates to a method of inhibiting a toxin in an animal, such as a human, by administering to the animal a therapeutically effective amount of a polymer having a plurality of pendant acid functional groups which are directly attached to the polymer backbone or attached to the polymer backbone by a spacer group. The spacer group can have a length in the range from 0 to about 20 atoms. The toxin is, typically, an exotoxin secreted by a pathogenic microorganism, such as a bacterium.Type: GrantFiled: May 11, 2000Date of Patent: September 18, 2001Assignee: GelTex Pharmaceuticals, Inc.Inventors: Caroline Isabelle Bacon Kurtz, Richard Fitzpatrick
-
Patent number: 6281252Abstract: A method for reducing oxalate levels in a patient that includes administering to the patient a therapeutically effective amount of non-absorbable amine polymers such as a polymer characterized by a repeat unit having the formula: and salts and copolymers thereof, where n is a positive integer and x is zero or an integer between 1 and about 4.Type: GrantFiled: September 25, 2000Date of Patent: August 28, 2001Assignee: GelTex Pharmaceutical, Inc.Inventors: Stephen Randall Holmes-Farley, W. Harry Mandeville, III
-
Patent number: 6271264Abstract: The present invention relates to a method for sequestering bile acids in a patient and to particular polymers for use in the method. The method comprises administering a therapeutically effective amount of a spirobicyclic ammonium moiety-containing polymer composition to a mammal, such as a human, whereby bile acids are sequestered. The polymers of the invention comprise spirobicyclic ammonium moieties and optionally, further comprise a hydrophobic substituent, a quaternary ammonium-containing substituent or a combination thereof.Type: GrantFiled: December 1, 1998Date of Patent: August 7, 2001Assignee: GelTex Pharmaceuticals, Inc.Inventors: Pradeep K. Dhal, Steven C. Polomoscanik
-
Patent number: 6270755Abstract: The present invention relates to a method of inhibiting a toxin in an animal, such as a human, by administering to the animal a therapeutically effective amount of a polymer having a plurality of pendant acid functional groups which are directly attached to the polymer backbone or attached to the polymer backbone by a spacer group. The spacer group can have a length in the range from 0 to about 20 atoms. The toxin is, typically, an exotoxin secreted by a pathogenic microorganism, such as a bacterium.Type: GrantFiled: April 3, 2000Date of Patent: August 7, 2001Assignee: GelTex Pharmaceuticals, Inc.Inventors: Caroline Isabelle Bacon Kurtz, Richard Fitzpatrick
-
Patent number: 6268126Abstract: The present invention relates to a method of treating a viral infection in an animal, such as a human, by administering to the animal a therapeutically effective amount of a polymer comprising a plurality of pendant hydrophobic groups and a plurality of pendant acid functional groups. The acid functional groups are connected directly to the polymer backbone or via an aliphatic spacer group of 1 to about 20 atoms in length.Type: GrantFiled: January 25, 2000Date of Patent: July 31, 2001Assignee: GelTex Pharmaceuticals, Inc.Inventors: Thomas X. Neenan, W. Harry Mandeville, III
-
Patent number: 6267952Abstract: The invention features a method for treating obesity in a patient by administering to the patient a polymer that has been substituted with one or more groups that inhibit lipases, which are enzymes responsible for the hydrolysis of fat. The invention further relates to the polymers employed in the methods described herein as well as novel intermediates and methods for preparing the polymers.Type: GrantFiled: October 5, 1998Date of Patent: July 31, 2001Assignee: GelTex Pharmaceuticals, Inc.Inventors: W. Harry Mandeville, III, Molly Kate Boie, Venkata R. Garigapati
-
Patent number: 6264937Abstract: The present invention relates to a method for treating obesity, a method for reducing the absorption of dietary fat, and a method for treating hypertriglyceridemia in a patient and to particular polymers for use in the methods or in a manufacture of a medicament. The methods comprise the step of orally administering to a mammal, such as a human, a therapeutically effective amount of one or more fat-binding polymers. The administration of the fat-binding polymer of the invention facilitates the removal of fat from the body prior to digestion, with minimal side effects and low toxicity. In a preferred embodiment, the one or more fat-binding polymers are administered in combination with one or more lipase inibitors, for example, lipstatin and tetrahydrolipstatin.Type: GrantFiled: October 5, 1998Date of Patent: July 24, 2001Assignee: GelTex Pharmaceuticals, Inc.Inventors: W. Harry Mandeville, III, George M. Whitesides, Stephen Randall Holmes-Farley
-
Patent number: 6264938Abstract: The invention relates to methods for treating hypercholesterolemia and atherosclerosis, and reducing serum cholesterol in a mammal. The methods of the invention comprise administering to a mammal a first amount of a bile acid sequestrant compound which is an unsubstituted polydiallylamine polymer and a second amount of an HMG Co-A reductase inhibitor compound. The first and second amounts together comprise a therapeutically effective amount. The invention further relates to pharmaceutical compositions useful for the treatment of hypercholesterolemia and atherosclerosis, and for reducing serum cholesterol. The pharmaceutical compositions comprise a combination of a first amount of an unsubstituted polydiallylamine polymer compound and a second amount of an HMG Co-A reductase inhibitor compound. The first and second amounts comprise a therapeutically effective amount. The pharmaceutical compositions of the present invention may optionally contain a pharmaceutically acceptable carrier.Type: GrantFiled: May 13, 1999Date of Patent: July 24, 2001Assignee: GelTex Pharmaceuticals, Inc.Inventors: Chad Cori Huval, Stephen Randall Holmes-Farley, John S. Petersen, Pradeep K. Dhal